The most significant improvements concerned arterial hypertension, stomatitis, and cutaneous toxicity. delay, corrected by cycle number, was 10% intended for both schedules. After the switch, 48. 7% of patients obtained a toxicity reduction (hypertension 82%, stomatitis 71%, cutaneous toxicity 69%). A reduction in on-off symptoms (86%) was achieved. Overall response rate was 40% and the disease control rate was 80%. Median progression-free survival was 16. 4 months and median overall survival was 41. 3 months. == Conclusions == Despite the small sample size and retrospective nature, we demonstrated the feasibility, safety, and efficacy from the alternative schedule, allowing prolonged treatment and better quality of life. == Key Points == == Intro == Sunitinib malate is an oral, multi-targeted, tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptors (VEGFR-1, VEGFR-2, and VEGFR-3) among other receptor tyrosine kinases [1]. Sunitinib competitively inhibits the binding of adenosine triphosphate to the tyrosine kinase domain name on targeted proteins at JW74 a concentration of 5100 nM. It is metabolized by cytochrome P450 3A4 to an active metabolite, SU12662, as well as to further inactive products. The pharmacokinetics is not affected by food intake [2]. Sunitinib continues to be approved intended for metastatic renal cell carcinoma (mRCC) in all treatment settings and for gastrointestinal stromal tumor therapy after disease progression (or intolerability) to imatinib mesylate therapy. Moreover, clinical studies confirm the activity of sunitinib in other several solid tumor types [3]. The landmark trial with sunitinib in mRCC was a double-blinded, randomized, phase III study enrolling 750 treatment-nave patients to receive sunitinib (experimental arm) or interferon- (IFN-, control arm) because first-line therapy. The primary endpoint was progression-free survival (PFS) and the trial was unblinded after a second interim analysis, demonstrating a significant benefit of sunitinib over IFN-: patients treated with sunitinib showed improved median PFS (11 vs . 5 months, p < 0. 001) and overall survival (OS, 26. 4 vs . 21. 8 months, p= 0. 051). Furthermore, differential OS was likely to be underestimated, owing to the significant rate of crossover from IFN- to sunitinib treatment after unblinding [1, 3]. The results of this study established sunitinib as a standard of care for the first-line treatment of mRCC; furthermore, the subsequent COMPARZ study confirmed the efficacy and toxicity profile of this drug in the same setting [4]. The conventional mRCC treatment with sunitinib is characterized by an on-off schedule, with daily oral administration of a 50-mg capsule for 4 weeks, followed by a 2-week break (4/2 schedule), with consecutive 6-week cycles [1, 3]. The dose of sunitinib can be modified in accordance to toxicity; nevertheless, a daily dose <25 mg is frequently reported as ineffective [2]. Although initial preclinical studies were planned to provide continuous administration, the 4/2 schedule was then selected intended for human experimentation at the ask for of the regulatory entities, to allow recovery from potential undesirable events (AEs) observed in pet models. Indeed, toxicological evaluation of such models exposed bone marrow depletion and toxic effects in rats and monkeys, as well as adrenal micro-hemorrhages in rats [3]. Sunitinib was JW74 associated with a higher incidence of treatment-related AEs compared with IFN-, with the most pronounced differences in the overall incidence of diarrhea (61 vs . 15%) and dysgeusia (46 vs . 15%). The most common AE of sunitinib, namely the fatigue, affects 5070% of patients and may be disabling. Hypothyroidism occurs in 4060% of patients. Bone marrow suppression with severe neutropenia is reported in 10% of patients. The most common grade 3 or 4 Rabbit Polyclonal to Synuclein-alpha AE is represented by hypertension (12%), followed by JW74 fatigue (11%), diarrhea (9%), and handfoot syndrome (9%) [1, 2]. In the sunitinib open access program, 8% of patients discontinued therapy because of serious AEs and a further 30% JW74 required dose reductions intended for toxicity [1]. In clinical practice, it is often.